sb 203580 has been researched along with Pemphigoid in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beckmann, T; Boehncke, WH; Hänsel, M; Hellberg, L; Holdorf, K; Kirchner, T; Laskay, T; Ludwig, RJ; Möckel, N; Recke, A; Samavedam, UKSRL; Schmidt, E; Solbach, W; Steinhorst, K; Zillikens, D | 1 |
1 other study(ies) available for sb 203580 and Pemphigoid
Article | Year |
---|---|
Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation.
Topics: Adult; Animals; Antigen-Antibody Complex; Autoantibodies; Butadienes; Dermis; Disease Models, Animal; Enzyme Inhibitors; Epidermal Cells; Epidermis; Epidermolysis Bullosa Acquisita; Glucocorticoids; Humans; Imidazoles; MAP Kinase Signaling System; Methylprednisolone; Mice; Mice, Inbred C57BL; Neutrophils; Nitriles; Pemphigoid, Bullous; Pyridines; Reactive Oxygen Species; Respiratory Burst | 2013 |